BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY : Impact Factor & More
eISSN: 1179-9889pISSN: 1179-9889
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY
Efficacy and Safety of CLAG-Based Sequential Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Non-Remission Relapsed or Refractory Acute Leukemia
- 27 Jul 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Metabolic Subtypes Predict Treatment Response in Acute Myeloid Leukemia: A Pilot Study.
- 1 Jun 2026
- Blood and lymphatic cancer : targets and therapy
A Risk Model Using Refined Disease Risk Index and 1-Month NK-Cell Count for Relapse in Children and Adults with T-ALL/LBL After Myeloablative Umbilical Cord Blood Transplantation
- 22 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia
- 19 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
Efficacy and Safety of CLAG-Based Sequential Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Non-Remission Relapsed or Refractory Acute Leukemia
- 27 Jul 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Metabolic Subtypes Predict Treatment Response in Acute Myeloid Leukemia: A Pilot Study.
- 1 Jun 2026
- Blood and lymphatic cancer : targets and therapy
A Risk Model Using Refined Disease Risk Index and 1-Month NK-Cell Count for Relapse in Children and Adults with T-ALL/LBL After Myeloablative Umbilical Cord Blood Transplantation
- 22 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia
- 19 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
FAQs on BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY
How long has BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY been actively publishing? 
What is the publishing frequency of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY?
How many articles did BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY publish last year?
What is the eISSN & pISSN for BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY?
Who is the publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations